SonoScape Medical Corp. (SHE:300633)
China · Delayed Price · Currency is CNY 23.42
+0.03 (0.13%)
May 15, 2026, 9:45 AM CST
SonoScape Medical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 2,340 | 2,290 | 2,000 | 2,108 | 1,752 | 1,435 |
Other Revenue | 19.39 | 19.39 | 14.2 | 12.65 | 10.73 | 9.27 |
| 2,360 | 2,309 | 2,014 | 2,120 | 1,763 | 1,445 | |
Revenue Growth (YoY) | 20.11% | 14.65% | -5.02% | 20.29% | 22.02% | 24.20% |
Cost of Revenue | 946.96 | 919.9 | 786.29 | 720.3 | 624.18 | 533.13 |
Gross Profit | 1,413 | 1,389 | 1,228 | 1,400 | 1,138 | 911.46 |
Selling, General & Admin | 843.9 | 821.75 | 710.04 | 616.63 | 521.16 | 457.37 |
Research & Development | 485.4 | 495.78 | 472.93 | 384.26 | 328.96 | 263.06 |
Other Operating Expenses | -50.44 | -52.04 | -61.66 | -72.96 | -52.56 | -35.46 |
Operating Expenses | 1,286 | 1,278 | 1,127 | 942.27 | 817.47 | 695.26 |
Operating Income | 126.91 | 111.27 | 100.97 | 457.68 | 320.99 | 216.21 |
Interest Expense | -3.48 | -4.16 | -6.7 | -5.05 | -3.7 | -5.55 |
Interest & Investment Income | 31 | 37.83 | 46.15 | 46.67 | 27.09 | 17.67 |
Currency Exchange Gain (Loss) | 4.51 | 4.51 | 1.63 | 6.84 | 17.97 | -7.05 |
Other Non Operating Income (Expenses) | -35.96 | -3.07 | -3.09 | -3.77 | -2.21 | 37.65 |
EBT Excluding Unusual Items | 122.99 | 146.38 | 138.96 | 502.36 | 360.14 | 258.92 |
Impairment of Goodwill | - | - | -55.91 | -15.44 | - | -36.98 |
Gain (Loss) on Sale of Investments | -0.4 | 0.16 | 3.56 | -12.84 | -3.93 | 3.17 |
Gain (Loss) on Sale of Assets | 0.03 | 0.03 | 0.05 | 0.02 | -0.74 | -0.19 |
Asset Writedown | -1.21 | -1.21 | -1.11 | -0.79 | -0.59 | -0.36 |
Other Unusual Items | 18.96 | 18.83 | 34.65 | 0.52 | 27.07 | 29.65 |
Pretax Income | 140.37 | 164.19 | 120.19 | 473.83 | 381.94 | 254.21 |
Income Tax Expense | -37.22 | -33.09 | -22.21 | 19.39 | 12.13 | 6.97 |
Net Income | 177.6 | 197.28 | 142.4 | 454.44 | 369.81 | 247.24 |
Net Income to Common | 177.6 | 197.28 | 142.4 | 454.44 | 369.81 | 247.24 |
Net Income Growth | 253.21% | 38.54% | -68.66% | 22.88% | 49.57% | - |
Shares Outstanding (Basic) | 429 | 429 | 432 | 429 | 430 | 399 |
Shares Outstanding (Diluted) | 429 | 429 | 432 | 433 | 430 | 399 |
Shares Change (YoY) | -0.64% | -0.61% | -0.30% | 0.65% | 7.83% | 3.44% |
EPS (Basic) | 0.41 | 0.46 | 0.33 | 1.06 | 0.86 | 0.62 |
EPS (Diluted) | 0.41 | 0.46 | 0.33 | 1.05 | 0.86 | 0.62 |
EPS Growth | 255.48% | 39.39% | -68.57% | 22.09% | 38.71% | - |
Free Cash Flow | -39.43 | -190.4 | 99.8 | 312.48 | 282.93 | 150.74 |
Free Cash Flow Per Share | -0.09 | -0.44 | 0.23 | 0.72 | 0.66 | 0.38 |
Dividend Per Share | 0.180 | 0.180 | 0.100 | 0.320 | 0.180 | 0.125 |
Dividend Growth | 80.00% | 80.00% | -68.75% | 77.78% | 44.00% | - |
Gross Margin | 59.87% | 60.16% | 60.96% | 66.03% | 64.59% | 63.09% |
Operating Margin | 5.38% | 4.82% | 5.01% | 21.59% | 18.21% | 14.97% |
Profit Margin | 7.53% | 8.54% | 7.07% | 21.43% | 20.98% | 17.11% |
Free Cash Flow Margin | -1.67% | -8.25% | 4.96% | 14.74% | 16.05% | 10.44% |
EBITDA | 211.14 | 192 | 167.7 | 507.71 | 356.61 | 247.77 |
EBITDA Margin | 8.95% | 8.32% | 8.33% | 23.95% | 20.23% | 17.15% |
D&A For EBITDA | 84.23 | 80.73 | 66.74 | 50.03 | 35.62 | 31.56 |
EBIT | 126.91 | 111.27 | 100.97 | 457.68 | 320.99 | 216.21 |
EBIT Margin | 5.38% | 4.82% | 5.01% | 21.59% | 18.21% | 14.97% |
Effective Tax Rate | - | - | - | 4.09% | 3.18% | 2.74% |
Revenue as Reported | 2,360 | 2,309 | 2,014 | 2,120 | 1,763 | 1,445 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.